10 Firms Dominate Monday Upsurge

4. BridgeBio Pharma Inc. (NASDAQ:BBIO)

BridgeBio Pharma (BBIO) traded 15.99 percent higher on Monday, closing the day at $33.73 as investor sentiment was buoyed by news that its newly approved drug called Attruby has seen a substantial demand with 430 prescriptions from 248 unique healthcare providers.

The early success highlights the medical community’s recognition of the need for new treatment options for patients with this progressive, fatal disease.

In addition, BridgeBio fully enrolled participants in three major market Phase 3 clinical trials. These include FORTIFY for the potential treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9); CALIBRATE for autosomal dominant hypocalcemia type 1 (ADH1); and PROPEL 3 for achondroplasia.

Each trial is expected to complete its last patient visit and release the results in the second half of the year.